Search

Biohaven Pharmaceutical announced findings pertaining to the benefit of Nurtec ODT - rimegepant - in decreasing the burden of butalbital use among migraine patients in real world clinical practice. Neurologist [...]

Biohaven Pharmaceutical announced new data from three late-breakers and three oral presentations supporting the safety and efficacy of Nurtec ODT and zavegepant nasal spray for the treatment of migraine. The [...]

(©Alamy; Getty Images) New York Pfizer spends its cash: Drugs giant Pfizer is spending the cash pile it built up from selling its Covid-19 vaccine and pills to buy the [...]

Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Biohaven, the maker of Nurtec ODT, an [...]

Reports Q1 revenue $319M, consensus $181.11M. Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, 'NURTEC ODT continues to be the leading migraine therapy in the oral CGRP [...]

2022 APR 28 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced two updates regarding Nurtec® ODT (rimegepant), [...]

Piper Sandler analyst Christopher Raymond says he's fielded numerous calls from investors 'expressing concern that something may be amiss' at Biohaven Pharmaceutical (BHVN) since the company departed from its pattern [...]

Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced that the parties have completed the collaboration transaction between the two companies. The transaction agreements, including Pfizer's commercialization of rimegepant and [...]

Biohaven Pharmaceutical Holding Company Ltd. and Pfizer Inc. announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT [...]

Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Biohaven Pharmaceutical with a $156 after the company reported 'another quarter of upside.' The pre-released Q3 Nurtec revenue of $136M [...]

Biohaven Pharmaceutical announced preliminary net product revenue of NURTEC ODT for the third quarter. Based on preliminary unaudited financial information, the company reported $136M in net product revenue from sales [...]

Biohaven Pharmaceutical announced that 17 abstracts, including three late-breaking presentations and four oral presentations, will be shared at the 2021 International Headache Society - European Headache Federation Joint Congress virtually [...]

Reports Q2 revenue $92.9M, consensus $78.13M. Vlad Coric, CEO of Biohaven commented, 'Once again, the Biohaven team has outperformed business expectations for our CGRP receptor antagonist platform. Demand for NURTEC [...]

Cowen analyst Ken Cacciatore raised the firm's price target on Biohaven Pharmaceutical to $130 from $90 and keeps an Outperform rating on the shares. Preliminary Nurtec revenue reached $93M in [...]

Biohaven Pharmaceutical announced preliminary net product revenue of NURTEC ODT for the second quarter of 2021. Based on preliminary unaudited financial information, the company reported $93M in net product revenue [...]

To advance the science of migraine treatment and aid the understanding of calcitonin gene-related peptide, or CGRP, monoclonal antibodies (mAbs) compared to oral CGRP receptor antagonists in the prevention of [...]

Cantor Fitzgerald analyst Charles Duncan raised the firm's price target on Biohaven Pharmaceutical to $140 from $125 and keeps an Overweight rating on the shares. The price target change is [...]

Biohaven Pharmaceutical Holding Company Ltd, a biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. [...]

Mizuho analyst Vamil Divan raised the firm's price target on Biohaven Pharmaceutical to $92 from $90 and keeps a Buy rating on the shares after the company announced that the [...]

Piper Sandler analyst Christopher Raymond says he's 'incrementally bullish' on the prospects of Biohaven Pharmaceutical's (BHVN) Nurtec and AbbVie's (ABBV) Ubrelvy following a survey of 96 neurologists. The results indicate [...]

Piper Sandler analyst Christopher Raymond reiterates an Overweight rating with a price target of $110 on Biohaven Pharmaceutical's shares after the company reported an in-line Q1 Nurtec quarter. Biohaven Pharmaceutical [...]

Biohaven is continuing to support the launch of NURTEC ODT and develop its product candidates through clinical and preclinical programs in a number of common and rare disorders. The Company [...]

Q1 revenue consensus $36.41M. Based on preliminary unaudited financial information, the company reported $43.8M in net product revenue from sales of NURTEC ODT in the first quarter. Total prescriptions of [...]

In an interview on CNBC's Mad Money, Dr. Vlad Coric said Biohaven has a heavy digital-first campaign which gives it an edge over competitors. 'We want people to treat their [...]

Biohaven Pharmaceutical announced that the U.S. FDA has filed and accepted for review its recently submitted supplemental New Drug Application for NURTEC ODT for the preventive treatment of migraine. The [...]

Canaccord analyst Sumant Kulkarni said he continues to like the Biohaven Pharmaceutical Nurtec story as he believes it has the potential to drive shareholder value. He noted prescriptions remain very [...]

Piper Sandler analyst Tyler Van Buren reiterates an Overweight rating on Biohaven Pharmaceutical with a $90 price target after experiencing a migraine and taking the company's Nurtec treatment. The drug [...]

Biohaven Pharmaceutical (BHVN) and Royalty Pharma (RPRX) announced that Biohaven has secured up to $250M in funding to advance the company's CGRP receptor antagonist program through the development of zavegepant. [...]

While AbbVie's (ABBV) atogepant Phase III migraine prevention study succeeded and the placebo-adjusted differences on migraine day reductions are better than Biohaven Pharmaceutical's (BHVN) Nurtec, the study's constipation signal in [...]